Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder
Abstract In Thailand, resource limitations lead many multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) patients to use off-label immunosuppressants. This study assesses the efficacy and safety of rituximab (RTX) with a CD19-based reinfusion regimen among Thai MS and NMOSD pa...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Nature Portfolio
2024-02-01
|
| Col·lecció: | Scientific Reports |
| Accés en línia: | https://doi.org/10.1038/s41598-024-53838-y |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|